Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.61 |
| ▸ | FNTA | P49354 | 1/20 | 0.59 |
| ▸ | FNTB | P49356 | 1/20 | 0.59 |
| ▸ | SQLE | Q14534 | 7/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ICMT | O60725 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8620659 | 0.85 | SQLE (0.60) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL8622485 | 0.82 | KMT2A (0.59) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL14249299 | 0.82 | SQLE (0.57) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL17867409 | 0.81 | KMT2A (0.57) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL8626304 | 0.79 | KMT2A (0.55) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL18897542 | 0.79 | KMT2A (0.67) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL16553971 | 0.78 | KMT2A (0.55) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL5487439 | 0.78 | KMT2A (0.55) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL8624990 | 0.78 | KMT2A (0.53) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL23802597 | 0.78 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321228-A1 | VACCINE ADJUVANTS AND METHODS OF SYNTHESIZING AND USING THE SAME | EUAGORE, LLC | 2023-10-12 | — | — | US | disclosed |
| WO-2022011031-A1 | VACCINE ADJUVANTS AND METHODS OF SYNTHESIZING AND USING THE SAME | Amyris, Inc. (US) | 2022-01-13 | — | — | WO | disclosed |
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321228-A1 | VACCINE ADJUVANTS AND METHODS OF SYNTHESIZING AND USING THE SAME | MYD88, TLR9, TLR5 | KMT2A 4287/4885MAPT 2956/4885MEN1 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.